To register for this face to face chapter event, click the Register link above.
New technologies, new regulations, an aging population, and patients taking more control of their health and wellness are just some of the trends causing transformation and disruption in how healthcare is delivered. We explore how life sciences, information technology and healthcare providers are collaborating and forming partner ecosystems to deliver healthcare in new ways and meeting the needs of patients leveraging a broad array of technologies: informatics, genomics, social, mobile, analytics and cloud technologies, making medicine more personal.
Join us as we hear from industry thought leaders on the new healthcare and how alliance ecosystems are key to it all.
Lisa Hagerty-McMahon, Principal, President and Founder of Hagerty-McMahon Biotech Consulting and President and Chairman of the Board of the BioPharma Consortium.
Lisa brings 20 years combined experience in alliance & program leadership across clinical development, NDA/BLA submissions and regulatory approval through commercial launch of small molecule and biologic medicines for serious unmet medical need including Naglazyme (Orphan metabolic disease - MPS VI), Orencia (Rheumatoid Arthritis), Vibativ (infectious disease - cSSSI/HAP) Xtandi (prostate cancer) and Avycaz (infectious disease - cIAI, cUTI).
She began her early career in clinical trials at the Stanford University School of Medicine after completing her thesis research investigating the effect of folic acid on homocysteine levels and additional risk factors for heart disease. Lisa brings a proven track record of leadership spanning alliances from small biotech to large pharmaceutical and complex public-private partnerships with multiple pharmaceutical, government and academic partners. She currently consults in deal sourcing and deal evaluation for biotech licensing and funding of novel technologies, drugs, and diagnostics.
Michael A. Goldman, Ph.D. Professor & Chair SF State Department of Biology
Professor Goldman teaches general genetics for biology majors, developmental biology for Cell & Molecular Biology majors, and an interdisciplinary course on the ethical issues in science and technology. He sees the public understanding of science as a key need if science and society are to thrive, speaking to professional and general groups whenever possible about various issues like stem cell biology for TV and radio call-in audiences.
He has written Op-Ed pieces or letters for the Los Angeles Times, the Wall Street Journal, the Sacramento Bee, the San Francisco Chronicle and the New York Times, as well as a variety of technical articles, including those appearing in Science and Nature Genetics. He is also an Associate Editor for Chromosome Research and a contributing editor to Bio-IT World. Professor Goldman believes the public learns much about science and bioethics from fiction, and reviews novels addressing various aspects of genetic science and its implications, in venues like Nature, Science, Nature Genetics and the San Francisco Chronicle.
Josephine Harada, Associate Director of Alliances. Illumina, Inc.
Dr. Harada advances strategic partnerships with an extensive network of biopharmaceutical and life science industry partners dedicated to advancing high-quality, evidence-based care. Prior to Illumina, Dr. Harada was Director of Strategic Alliances at Foundation Medicine, a molecular information company at the forefront of bringing comprehensive genomic analysis to routine cancer care. Dr. Harada has additionally held Product Management functions at Life Technologies and Generation Health, a pharmacogenomics medicines company acquired by CVS Caremark, where she worked with the company’s leadership teams to drive critical reimbursement and regulatory strategies in parallel with the development and commercialization of multiple diagnostic tests.
Josephine started her scientific career at the Genomics Institute of the Novartis Research Foundation developing advanced genomic technologies. A passionate advocate of genomic medicine, Dr. Harada remains committed to the development of genomic innovator products and molecular therapies, and to accelerating the adoption of personalized medicine interventions into mainstream care.
Dr. Harada received a Ph.D. from UCLA, an MBA from the Wharton School at the University of Pennsylvania, and a BS from the Massachusetts Institute of Technology.
Alan Lindsay, Senior Director, Healthcare & Life Sciences Industry Alliances, Salesforce.com
Alan leads the healthcare and life sciences industry alliance strategy and cross-functional execution of joint solutions and partnerships for the vertical. Alan’s focus is on developing repeatable, industry-focused solutions with partners to help transform healthcare and life sciences.
Prior to joining Salesforce, Alan spent 15+ years in the technology industry focused on building strategic go-to-market partnerships, including the last 12 years at Oracle and Hyperion Solutions. At Oracle, Alan led a team responsible for Oracle’s North America CRM and Customer Experience (CX) alliances and channels, driving go-to-market and revenue generating initiatives across multiple products, market segments, and industries with key SI & ISV partners.
Alan holds a BBA in Finance and Risk Management from the University of Georgia and an MBA in Marketing and IT from Vanderbilt University. Alan resides in Atlanta, GA with his wife and three children.
Dave Schulte, Healthcare Venture Capital, McKesson Ventures